Lee, H. C., Bumma, N., Richter, J., Dhodapkar, M., Hoffman, J. E., Suvannasankha, A., Zonder, J., Shah, M. R., Lentzsch, S., Maly, J. J., Ye, J. C., Wu, K. L., Deveaux, M., Chokshi, D., Boyapati, A., Hazra, A., Lorenc, K. R., Kroog, G., Houvras, Y., & Jagannath, S. (2023). S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere, 7(S3), e1610068. https://doi.org/10.1097/01.hs9.0000967700.16100.68

Brown, J. R., Eichhorst, B., Ghia, P., Jurczak, W., Kahl, B., Lamanna, N., Robak, T., Shadman, M., Tam, C., Qiu, L., Cohen, A., Zhang, M., Salmi, T., Paik, J., Wang, L., Zhang, J., MA, H., & Tedeschi, A. (2023). P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE. HemaSphere, 7(S3), e356884b. https://doi.org/10.1097/01.hs9.0000969428.35688.4b

Brivio, E., Pennesi, E., Willemse, M., Jiang, Y., van der Velden, V., Beverloo, B., Hudson, C., Kuttschreuter, L., van der Sluis, I., Brethon, B., Bautista, F., J. Burke, M., Heerema, N., Bukowinski, A., Cooper, S., Pollard, J., Nagasubramani, R., Redell, M., Bourquin, J.-P., … Zwaan, M. (2023). P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA. HemaSphere, 7(S3), e506783a. https://doi.org/10.1097/01.hs9.0000969608.50678.3a

Hernandez-Trujillo, V., Zhou, C., Scalchunes, C., Ochs, H. D., Sullivan, K. E., Cunningham-Rundles, C., Fuleihan, R. L., Bonilla, F. A., Petrovic, A., Rawlings, D. J., & de la Morena, M. T. (2023). A Registry Study of 240 Patients with X-Linked Agammaglobulinemia Living in the USA. Journal of Clinical Immunology, 43(6), 1468–1477. https://doi.org/10.1007/s10875-023-01502-x

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dasgupta, K., & Cardoso, A. P. T. (2023). PB1980: ASC4KIDS: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. HemaSphere, 7(S3), e1669755. https://doi.org/10.1097/01.hs9.0000974736.16697.55

Kim, W.-S., Shortt, J., Luigi Zinzani, P., Mikhaylova, N., Marin-Niebla, A., Radeski, D., Ribrag, V., Domingo Domènech, E., Sawas, A., Alexis, K., Emig, M., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2023). P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY. HemaSphere, 7(S3), e6843062. https://doi.org/10.1097/01.hs9.0000971464.68430.62

Kater, A., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Thadani-Mulero, M., Lefebure, M., Jiang, Y., Millen, R., Boyer, M., & Seymour, J. F. (2023). S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL). HemaSphere, 7(S3), e492813f. https://doi.org/10.1097/01.hs9.0000967716.49281.3f

Alsina, M., Dhodapkar, M., Berdeja, J., Patel, K., Richard, S., Vij, R., Leleu, X., Egan, D., Leif Bergsagel, P., Ran, R., Usmani, S. Z., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Zhong, X., Greggio, C., Popa Mckiver, M., Carrasco Alfonso, M., & Siegel, D. (2023). P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C. HemaSphere, 7(S3), e90596a3. https://doi.org/10.1097/01.hs9.0000970388.90596.a3

Lamanna, N., Tam, C., Jurczak, W., Kontos, A., Konig, H., Ruppert, A. S., & Tsai, D. E. (2023). P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. HemaSphere, 7(S3), e724362f. https://doi.org/10.1097/01.hs9.0000971248.72436.2f

Eichhorst, B., Lamanna, N., O’brien, S., Tam, C., Qiu, L., Yang, K., Wu, K., Salmi, T., Barnes, G., & Brown, J. R. (2023). P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL). HemaSphere, 7(S3), e02428b9. https://doi.org/10.1097/01.hs9.0000969464.02428.b9

Shadman, M., Manzoor, B. S., Sail, K., Tuncer, H. H., Allan, J. N., Ujjani, C., Emechebe, N., Kamalakar, R., Coombs, C. C., Leslie, L., Barr, P. M., Brown, J. R., Eyre, T. A., Rampotas, A., Schuh, A., Lamanna, N., Skarbnik, A., Roeker, L. E., Bannerji, R., … Mato, A. R. (2023). Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical Lymphoma Myeloma and Leukemia, 23(7), 515–526. https://doi.org/10.1016/j.clml.2023.03.010

Anim-Koranteng, C., Akpoigbe, O., Miller, M., & Averbukh, Y. (2023). From Studio to Rehab: A Debilitating Form of Anti-HMGCR Myopathy. Cureus. https://doi.org/10.7759/cureus.40825

Amengual, J. E., Reagan, P., Li, H., Saeed, H., Vaidya, R., Unger, J. M., Danilov, A., LeBlanc, M., Friedberg, J. W., & Smith, S. M. (2023). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL. Hematological Oncology, 41(S2), 842–843. Portico. https://doi.org/10.1002/hon.3166_ot22

Brown, J. R., Eichorst, B., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Cohen, A., Zhang, M., Salmi, T., Paik, J., Wang, L., Zhang, J., Ma, H., & Tedeschi, A. (2023). Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety database. Hematological Oncology, 41(S2), 459–461. Portico. https://doi.org/10.1002/hon.3164_339

Lee, H., Choi, M., Siddiqi, T., Rhodes, J., Wierda, W., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J., Leslie, L., Goldenberg, A., Chung, G., Breitmeyer, J., Yazji, S., Shih, T., Wang, M., Jamieson, C., & Kipps, T. (2023). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Hematological Oncology, 41(S2), 587–589. Portico. https://doi.org/10.1002/hon.3164_440

Kater, A. P., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., Serna, J. d. l., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Thadani‐Mulero, M., Lefebure, M., Jiang, Y., Millen, R., Boyer, M., & Seymour, J. F. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology, 41(S2), 239–242. Portico. https://doi.org/10.1002/hon.3163_156

Jurczak, W., Lamanna, N., Tam, C. S., Kontos, A., Konig, H., Ruppert, A. S., & Tsai, D. E. (2023). COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. Hematological Oncology, 41(S2), 758–759. Portico. https://doi.org/10.1002/hon.3165_605

Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Yang, K., Wu, K., Salmi, T., Barnes, G., & Brown, J. R. (2023). Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health‐related quality of life. Hematological Oncology, 41(S2), 463–464. Portico. https://doi.org/10.1002/hon.3164_341

Askanase, A., Stach, C., Brittain, C., Stojan, G., & Furie, R. (2023). POS0115 DAPIROLIZUMAB PEGOL EFFICACY BY SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A POST HOC ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2023-eular.1991

Wang, M. L., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I., Tessoulin, B., Alencar, A. J., Ma, S., Lewis, D., Lech-Maranda, E., Rhodes, J., Patel, K., Maddocks, K., Lamanna, N., … Shah, N. N. (2023). Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. Journal of Clinical Oncology, 41(24), 3988–3997. https://doi.org/10.1200/jco.23.00562

Askanase, A. D., Tang, W., Zuraw, Q., Gordon, R., Brotherton, B., & Merrill, J. T. (2023). Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE. Lupus Science & Medicine, 10(1), e000875. https://doi.org/10.1136/lupus-2022-000875

Sivakumar, S., Jin, D. X., Rathod, R., Ross, J., Cantley, L. C., Scaltriti, M., Chen, J. W., Hutchinson, K. E., Wilson, T. R., Sokol, E. S., & Vasan, N. (2023). Genetic Heterogeneity and Tissue-specific Patterns of Tumors with MultiplePIK3CAMutations. Clinical Cancer Research, 29(6), 1125–1136. https://doi.org/10.1158/1078-0432.ccr-22-2270

Kallash, M., Wang, Y., Smith, A., Trachtman, H., Gbadegesin, R., Nester, C., Canetta, P., Wang, C., Hunley, T. E., Sperati, C. J., Selewski, D., Ayoub, I., Srivastava, T., Mottl, A. K., Kopp, J., Gillespie, B., Robinson, B., Chen, D., … Steinke, J. (2023). Rapid Progression of Focal Segmental Glomerulosclerosis in Patients with High-Risk APOL1 Genotypes. Clinical Journal of the American Society of Nephrology, 18(3), 344–355. https://doi.org/10.2215/cjn.0000000000000069

Maniar, R., Gallitano, S. M., Husain, S., Moazami, G., Weiss, M. J., & Shu, C. A. (2023). Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition. Journal of the National Comprehensive Cancer Network, 21(3), 232–234. https://doi.org/10.6004/jnccn.2022.7084

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2023). Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 388(4), 319–332. https://doi.org/10.1056/nejmoa2211582

Brown, J. R., Eichhorst, B., Hillmen, P., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Kaźmierczak, M., Jurczak, W., Zhou, K., Šimkovič, M., Mayer, J., Gillespie-Twardy, A. L., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2022). Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. Blood, 140(Supplement 2), LBA-6-LBA-6. https://doi.org/10.1182/blood-2022-171538

Byrd, J. C., Woyach, J. A., Furman, R. R., Martin, P., O’Brien, S., Brown, J. R., Stephens, D. M., Barrientos, J. C., Patten, P. E., Munir, T., Patel, K., Butturini, A., de Borja, M., Wang, M. H., Jain, N., & Wierda, W. G. (2022). Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up. Blood, 140(Supplement 1), 9865–9867. https://doi.org/10.1182/blood-2022-159542

Blachly, J. S., Stephens, D. M., Ye, J. C., Lamanna, N., Jain, N., Niesman, M., Zhang, K., & Woyach, J. A. (2022). Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL. Blood, 140(Supplement 1), 2324–2325. https://doi.org/10.1182/blood-2022-171203

Davids, M. S., Sharman, J. P., Eyre, T. A., Woyach, J. A., de Miranda, P. A. P., Shahkarami, M., Butturini, A., Emeribe, U., & Byrd, J. C. (2022). Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features. Blood, 140(Supplement 1), 4173–4175. https://doi.org/10.1182/blood-2022-157018

Batlevi, C. L., Salles, G., Park, S. I., Phillips, T. J., Amengual, J. E., Andorsky, D., Campbell, P., McKay, P., Leonard, J. P., Sondhi, M., Chen, Y., Slatcher, P. L., Lin, R., Szanto, A., Abbadi, S., & Morschhauser, F. (2022). Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1. Blood, 140(Supplement 1), 2296–2298. https://doi.org/10.1182/blood-2022-166991

Mahadeo, K. M., Baiocchi, R. A., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Nikiforow, S., Reshef, R., Ye, W., & Prockop, S. (2022). New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood, 140(Supplement 1), 10374–10376. https://doi.org/10.1182/blood-2022-157766

Wierda, W. G., Lewis, D. J., Ghia, P., Shah, N. N., Coombs, C. C., Cheah, C. Y., Lamanna, N., Rhodes, J. M., Hoffmann, M., Ma, S., Eyre, T. A., Munir, T., Patel, M. R., Alencar, A. J., Tam, C. S., Seymour, J. F., Jurczak, W., Lech-Marańda, E., Roeker, L. E., … Mato, A. R. (2022). Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 846–849. https://doi.org/10.1182/blood-2022-157058

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dasgupta, K., & Ramscar, N. (2022). ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 140(Supplement 1), 12204–12205. https://doi.org/10.1182/blood-2022-162451

Lee, H. J., Choi, M. Y., Siddiqi, T., Rhodes, J. M., Wierda, W. G., Isufi, I., Tuscano, J. M., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, M., Jamieson, C., & Kipps, T. J. (2022). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood, 140(Supplement 1), 566–568. https://doi.org/10.1182/blood-2022-167153

Esplin, I., Huang, Y., Bhat, S. A., Grantier, C., Grever, M. R., Hoffman, C., Kittai, A. S., Lucas, M. S., Moran, M. E., Reid, M., Suresh, S., Woyach, J. A., & Rogers, K. A. (2022). Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study. Blood, 140(Supplement 1), 4166–4168. https://doi.org/10.1182/blood-2022-167314

Mohyuddin, G. R., Chakraborty, R., Calip, G., Ascha, M. S., Wang, X., Rubinstein, S., Tuchman, S. A., Costa, L. J., Haaland, B., Giri, S., Mian, H. S., Fonseca, R., & Sborov, D. W. (2022). Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy. Blood, 140(Supplement 1), 5223–5224. https://doi.org/10.1182/blood-2022-165541

Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L. C., Izutsu, K., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., & Horwitz, S. M. (2022). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis. Blood, 140(Supplement 1), 9387–9389. https://doi.org/10.1182/blood-2022-169432

Seymour, J. F., Byrd, J. C., Munir, T., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O’Brien, S., Brown, J. R., Mato, A. R., Stilgenbauer, S., Fehn, T., de Miranda, P. A. P., Higgins, K., John, E., de Borja, M., Jurczak, W., & Woyach, J. A. (2022). Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 140(Supplement 1), 7050–7052. https://doi.org/10.1182/blood-2022-157060

Shah, N. N., Wang, M. L., Brown, J. R., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Gastinne, T., Ghia, P., Lamanna, N., Hoffmann, M., Patel, M. R., Flinn, I. W., Gerson, J. N., Ma, S., Coombs, C. C., … Mato, A. R. (2022). Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 4127–4132. https://doi.org/10.1182/blood-2022-159035

Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Marańda, E., Lamanna, N., Tam, C. S., Seymour, J. F., Shah, N. N., Coombs, C. C., Ujjani, C. S., Patel, M. R., Fakhri, B., Cheah, C. Y., Alencar, A. J., Cohen, J. B., … Jurczak, W. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 2316–2320. https://doi.org/10.1182/blood-2022-159497

Wang, M. L., Shah, N. N., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I. W., Tessoulin, B., Alencar, A. J., Ma, S., Lech-Marańda, E., Rhodes, J. M., Patel, K., Woyach, J. A., Lamanna, N., … Mato, A. R. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 9368–9372. https://doi.org/10.1182/blood-2022-159425

Gold, J. A. W., Tolu, S. S., Chiller, T., Benedict, K., & Jackson, B. R. (2021). Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors—United States, July 2016–June 2019. Clinical Infectious Diseases, 75(2), 334–337. https://doi.org/10.1093/cid/ciab1026

Hillmen, P., Brown, J., Lamanna, N., O’Brien, S., Tam, C., Qiu, L., Yang, K., Barnes, G., Wu, K., Salmi, T., & Eichhorst, B. (2022). P663: HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH ZANUBRUTINIB VS IBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (RR) CLL/SLL: RESULTS FROM THE RANDOMIZED PHASE 3 ALPINE TRIAL. HemaSphere, 6, 561–562. https://doi.org/10.1097/01.hs9.0000845536.66920.d3

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Bayar, M. A., & Ramscar, N. (2022). PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). HemaSphere, 6, 1782–1783. https://doi.org/10.1097/01.hs9.0000850464.45271.b3

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S. N., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Gu, L., Tan, A., Chao, M., O’Hear, C., Lal, I., Vyas, P., & Daver, N. (2022). S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS. HemaSphere, 6, 67–68. https://doi.org/10.1097/01.hs9.0000843556.59348.1d

Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., … Cheah, C. Y. (2022). P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. HemaSphere, 6, 991–992. https://doi.org/10.1097/01.hs9.0000847272.47630.ff

Mato, A. R., Pagel, J. M., Coombs, C. C., Shah, N. N., Lamanna, N., Munir, T., Lech-Maranda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, M. R., Fakhri, B., Barve, M. A., Tam, C., Lewis, D., Gerson, J. N., … Jurczak, W. (2022). S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. HemaSphere, 6, 48–49. https://doi.org/10.1097/01.hs9.0000843480.04890.cc

Prockop, S., Beitinjaneh, A., Choquet, S., Dahiya, S., Dinavahi, R., Farah, R., Gamelin, L., Ghobadi, A., Mehta, A., Nayak, P., Reshef, R., Satyanarayana, G., Stiff, P., Ye, W., & Mahadeo, K. M. (2022). S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE). HemaSphere, 6, 157–158. https://doi.org/10.1097/01.hs9.0000843916.04522.0a

Pal, I., Grilo, A. M. S., Gaspary, A., Das Sharma, S., Scotto, L., O’Connor, O. A., Jovanovic, M., Deng, C., & Berchowitz, L. E. (2022). Inhibition of casein kinase 1δ disrupts translation initiation and exerts potent antilymphoma activity. Blood Advances, 6(14), 4157–4161. https://doi.org/10.1182/bloodadvances.2021006833

Diamond, J. R., Boni, V., Lim, E., Nowakowski, G., Cordoba, R., Morillo, D., Valencia, R., Genvresse, I., Merz, C., Boix, O., Frigault, M. M., Greer, J. M., Hamdy, A. M., Huang, X., Izumi, R., Wong, H., & Moreno, V. (2022). First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research, 28(7), 1285–1293. https://doi.org/10.1158/1078-0432.ccr-21-3617